EA199900002A1 - Способ получения лекарственного комплекса - Google Patents

Способ получения лекарственного комплекса

Info

Publication number
EA199900002A1
EA199900002A1 EA199900002A EA199900002A EA199900002A1 EA 199900002 A1 EA199900002 A1 EA 199900002A1 EA 199900002 A EA199900002 A EA 199900002A EA 199900002 A EA199900002 A EA 199900002A EA 199900002 A1 EA199900002 A1 EA 199900002A1
Authority
EA
Eurasian Patent Office
Prior art keywords
spacer
drug compound
bound
carboxyl groups
polysaccharide derivative
Prior art date
Application number
EA199900002A
Other languages
English (en)
Other versions
EA001897B1 (ru
Inventor
Казухиро Иноуе
Хироси Сусаки
Масахиро Икеда
Original Assignee
Дайити Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дайити Фармасьютикал Ко., Лтд. filed Critical Дайити Фармасьютикал Ко., Лтд.
Publication of EA199900002A1 publication Critical patent/EA199900002A1/ru
Publication of EA001897B1 publication Critical patent/EA001897B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Способ получения лекарственного комплекса, в котором производное полисахарида, имеющего карбоксильные группы, и остаток лекарственного соединения связаны друг с другом с помощью спейсера, содержащего аминокислоту или пептидносвязанные 2-8 аминокислоты, или лекарственного комплекса, в котором полисахаридное производное, имеющее карбоксильные группы, и остаток лекарственного соединения связаны друг с другом без помощи спейсера, заключающийся в том, что соль органического амина и полисахаридного производного, имеющего карбоксильные группы, взаимодействует с лекарственным соединением или со спейсером, связанным с лекарственным соединением, в безводной системе. Взаимодействие между полисахаридным производным, имеющим карбоксильные группы и лекарственным соединением, связанным со спейсером или т. п., может проводиться с высокими выходами, и если этому взаимодействию подвергается лекарственное соединение, имеющее лактоновый цикл, побочные реакции могут быть уменьшены.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA199900002A 1996-06-06 1997-06-05 Способ получения лекарственного комплекса EA001897B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14452296 1996-06-06
PCT/JP1997/001915 WO1997046261A1 (en) 1996-06-06 1997-06-05 Process for producing drug complexes

Publications (2)

Publication Number Publication Date
EA199900002A1 true EA199900002A1 (ru) 1999-08-26
EA001897B1 EA001897B1 (ru) 2001-10-22

Family

ID=15364300

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199900002A EA001897B1 (ru) 1996-06-06 1997-06-05 Способ получения лекарственного комплекса

Country Status (16)

Country Link
US (1) US6291671B1 (ru)
EP (1) EP0955064B1 (ru)
JP (1) JP4137184B2 (ru)
CN (1) CN1227034C (ru)
AT (1) ATE273716T1 (ru)
AU (1) AU723442B2 (ru)
CA (1) CA2257233A1 (ru)
DE (1) DE69730352T2 (ru)
DK (1) DK0955064T3 (ru)
EA (1) EA001897B1 (ru)
ES (1) ES2229355T3 (ru)
ID (1) ID17243A (ru)
NO (1) NO323626B1 (ru)
PT (1) PT955064E (ru)
TW (1) TW409058B (ru)
WO (1) WO1997046261A1 (ru)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
CN1250293C (zh) * 1998-05-22 2006-04-12 第一制药株式会社 药物复合物
AU2001267831A1 (en) * 2000-06-29 2002-01-08 Daiichi Pharmaceutical Co., Ltd. DDS compound and process for the preparation thereof
EP1401875A4 (en) * 2001-05-04 2005-01-26 Univ Utah Res Found HYALURONIC ACID-CONTAINING BIOKON JUGATES: TARGETED DELIVERY OF ANTIBODIES TO CANCER CELLS
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20050169883A1 (en) * 2002-05-06 2005-08-04 Prestwich Glenn D. Preblocking with non-ha gags increases effectiveness of ha conjugated anticancer agents
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
CA2912012C (en) 2005-05-05 2018-05-29 Sensient Flavors Inc. Production of beta-glucans and mannans
WO2007004675A1 (ja) * 2005-07-06 2007-01-11 Seikagaku Corporation 薬剤導入光架橋ヒアルロン酸誘導体ゲル
ITPD20050242A1 (it) 2005-08-03 2007-02-04 Fidia Farmaceutici Bioconiugati antitumorali dell'acido ialuronico o dei suoi derivati, ottenibili per coniugazione chimica diretta o indiretta, e loro impiego in campo farmaceutico
CN1973902B (zh) * 2006-12-12 2010-11-10 东北师范大学 以人参多糖为载体的抗肿瘤药物阿霉素复合物及制备方法
ES2853204T3 (es) 2010-05-25 2021-09-15 Syndevrx Inc Inhibidores de MetAP2 conjugado con polímero, y métodos terapéuticos de uso de los mismos
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
SI3342785T1 (sl) 2012-10-11 2020-02-28 Daiichi Sankyo Company, Limited Povezovalci za konjugate protitelesa in zdravila
US9872924B2 (en) 2012-10-19 2018-01-23 Daiichi Sankyo Company, Limited Antibody-drug conjugate produced by binding through linker having hydrophilic structure
ES2902082T3 (es) 2013-04-10 2022-03-24 Syndevrx Inc Inhibidores de MetAP2 Fumagillol conjugados a polímero o modificados para mejorar o restaurar la sensibilidad a la insulina
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP3088419B1 (en) 2013-12-25 2018-10-10 Daiichi Sankyo Company, Limited Anti-trop2 antibody-drug conjugate
CN110464847B (zh) 2014-01-31 2024-02-09 第一三共株式会社 抗her2抗体－药物偶联物
EP3130608B1 (en) 2014-04-10 2019-09-04 Daiichi Sankyo Co., Ltd. (anti-her2 antibody)-drug conjugate
SG10201907807XA (en) 2014-04-10 2019-09-27 Daiichi Sankyo Co Ltd Anti-her3 antibody-drug conjugate
CA2990572C (en) 2015-06-29 2022-07-26 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CN108290853B (zh) 2015-12-10 2022-05-31 辛德弗雷克斯公司 烟曲霉醇衍生物及其多晶型物
MX2018008321A (es) 2016-01-11 2018-09-21 Syndevrx Inc Tratamiento de tumores ocasionados por disfuncion metabolica.
JPWO2018110515A1 (ja) 2016-12-12 2019-10-24 第一三共株式会社 抗体−薬物コンジュゲートと免疫チェックポイント阻害剤の組み合わせ
US11434289B2 (en) 2017-01-17 2022-09-06 Daiichi Sankyo Company, Limited Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate
TWI794230B (zh) 2017-05-15 2023-03-01 日商第一三共股份有限公司 抗ｃｄｈ６抗體及抗ｃｄｈ６抗體-藥物結合物、以及其製造方法
IL272964B2 (en) 2017-08-31 2024-02-01 Daiichi Sankyo Co Ltd Production method for antibody-drug conjugates
US11945882B2 (en) 2017-08-31 2024-04-02 Daiichi Sankyo Company, Limited Method for producing antibody-drug conjugate
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
CA3117666A1 (en) 2018-10-26 2020-04-30 Syndevrx, Inc. Biomarkers of metap2 inhibitors and applications thereof
AU2020309570A1 (en) 2019-07-10 2022-02-03 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
MX2022000450A (es) 2019-07-10 2022-04-25 Cybrexa 3 Inc Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos.
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982000762A1 (en) * 1980-09-03 1982-03-18 Daigo H Agent for alimentary canal
JPS5746920A (en) * 1980-09-03 1982-03-17 Kyosei Seiyaku Kk Drug for digestive tract
JPS59220197A (ja) 1983-05-30 1984-12-11 Snow Brand Milk Prod Co Ltd 新規な含窒素多糖体およびその製造方法
JP2604930B2 (ja) 1990-12-14 1997-04-30 株式会社ディ・ディ・エス研究所 ヒアルロン酸およびコンドロイチン誘導体
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
JPH0784481B1 (ru) 1991-02-21 1995-09-13
JP3359955B2 (ja) 1992-07-16 2002-12-24 第一製薬株式会社 抗腫瘍剤
DK0640622T3 (da) * 1993-02-26 2000-10-23 Drug Delivery System Inst Ltd Polysaccharidderivat og lægemiddelbærer
JPH0784481A (ja) 1993-06-26 1995-03-31 Ricoh Co Ltd 画像形成装置
SG50747A1 (en) 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
TW527183B (en) 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts

Also Published As

Publication number Publication date
AU723442B2 (en) 2000-08-24
DE69730352T2 (de) 2005-09-08
EA001897B1 (ru) 2001-10-22
PT955064E (pt) 2004-10-29
EP0955064A1 (en) 1999-11-10
ATE273716T1 (de) 2004-09-15
US6291671B1 (en) 2001-09-18
CN1227034C (zh) 2005-11-16
WO1997046261A1 (en) 1997-12-11
NO323626B1 (no) 2007-06-18
ID17243A (id) 1997-12-11
NO985667D0 (no) 1998-12-04
EP0955064A4 (en) 2000-12-06
JP4137184B2 (ja) 2008-08-20
ES2229355T3 (es) 2005-04-16
DE69730352D1 (de) 2004-09-23
CA2257233A1 (en) 1997-12-11
EP0955064B1 (en) 2004-08-18
TW409058B (en) 2000-10-21
CN1227500A (zh) 1999-09-01
AU2978897A (en) 1998-01-05
NO985667L (no) 1999-02-04
DK0955064T3 (da) 2004-12-06

Similar Documents

Publication Publication Date Title
EA199900002A1 (ru) Способ получения лекарственного комплекса
NO985666L (no) Medikamentkompleks
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
EP0387567A3 (en) Amphoteric polyelectrolyte, method for production thereof, and organic sludge dehydrater
NO177004C (no) Analogifremgangsmåte for fremstilling av 7-substituerte derivater av 3,5-dihydroksyhept-6-ynsyre
DE59006824D1 (de) Verfahren zum immobilisieren von proteinen, peptiden, coenzymen od.dgl. an einem träger.
NO165626C (no) Fremgangsmaate for aa opploeseliggjoere en hydrofob, terapeutisk aktiv, organisk forbindelse, spesielt en n-acyl-indol.
CA2399187A1 (en) Kahalalide compounds
AU587827B2 (en) Oligopeptide derivatives, their production and their use as surfactantes kind to the skin
ES2101953T3 (es) Compuestos de cerio iv organicos y su preparacion y utilizacion.
BG50164A3 (en) Method for preparing of amicacine
MY131384A (en) Novel 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
CA2151543A1 (en) Immunogens for the production of cocaine-hydrolyzing catalytic antibodies
SE8502315D0 (sv) Improved transamination process for producing amino acids
ES542956A0 (es) Un procedimiento para preparar un derivado de oxazolina
RU93004665A (ru) Микробиологический способ гидроксилирования азот-гетероциклических-карбоновых кислот
PT83837A (de) Verfahren zur herstellung von peptiden unter der verwendung von perchloraten
AU629008B2 (en) Compounds from biopolymrs and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof
EP0344791A3 (en) Process for the enzymatic resolution of the optical isomers of racemic ester derivatives of 3-mercapto-2-alkyl-propionic acid
FI885638A (fi) Menetelmä lääkeaineina käyttökelpoisten griseoliinihappomonoesterijohdannaisten valmistamiseksi
EP0226132A3 (de) Dipeptide mit C-terminalem Phosphinothricin, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung unerwünschten Pflanzenwuchses
TH26735A (th) กระบวนการสำหรับการลดคอนเทนต์ผลพลอยได้ของคาร์เบนเดซิม
AT387380B (de) Verfahren und zwischenprodukte fuer n-(s-3alkyl-heptanoyl)-d-gamma-glutamyl-glycyl-dalanin
RU95115861A (ru) Способ получения мурамилпептидов
DE68905188D1 (de) Fermentationsprozess fuer carboxylsaeuren.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU